Live Markets: Brainy efforts underway, but still some way to go for neuro drug developers

Neumora Therapeutics

01/11/2024 15:38

* 
      Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3%
    

        * 
      Cons Disc leads S&P sector gainers; Utilities sole loser
    

        * 
      Euro STOXX 600 index up 1.3%
    

        * 
      Dollar rises; gold edges up; crude, up >1%, bitcoin up
0.4%
    

        * 
      U.S. 10-Year Treasury yield edges up to ~4.33%
    

  
Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
     
     
    BRAINY EFFORTS UNDERWAY, BUT STILL SOME WAY TO GO FOR NEURO
DRUG DEVELOPERS
    An unmet need in neurological conditions has stirred up
anticipation for trial data for drugs being developed for
neurological conditions like depression, Alzheimer's disease,
and dementia that affect millions of patients worldwide,
Canaccord Genuity analysts said on Friday. 
    The brokerage said some recent wins with Eisai  4523.T  and
Biogen's  BIIB.O  Leqembi and Eli Lilly's  LLY.N  Kisunla for
Alzheimer's, along with Bristol Myers Squibb's  BMY.N  Cobenfy
for schizophrenia, represent significant advances in their
fields.
    It estimates that about 57 products are in development for
major depressive disorder, including 14 for treatment-resistant
depression, 11 for bipolar depression, and 5 for postpartum
depression that affects new mothers. 
    Canaccord said it is looking forward to late-stage trial
data from Johnson & Johnson's  JNJ.N  aticaprant and Neumora
Therapeutics'  NMRA.O  navacaprant, both in development for
major depressive disorder.
    "Overall, we believe biopharma's depression-focused pipeline
remains healthy" said Canaccord, but added that there was still
a long way to go due to some diseases being poorly understood. 
    Canaccord added that successes in Alzheimer's with Leqembi
and Kisunla have come despite the challenges in understanding
such neurodegenerative conditions.
    Among newer drugs in development, the brokerage highlighted
Roche's  ROG.S  trontinemab, designed to ferry the drug across
the blood brain barrier—protective blood vessels that prevent
chemicals in the bloodstream from entering the brain - in hopes
of getting more of the treatment into the brain. 
    Canaccord said Cervomed's  CRVO.O  neflamapimod could be a
"major advance for patients."
    Cervomed is developing the drug to treat dementia with Lewy
bodies, the second most common type of dementia after
Alzheimer's and an indication that sees fewer investments, said
Canaccord. 
    (Christy Santhosh)
    *****

   

    FOR FRIDAY'S EARLIER LIVE MARKETS POSTS:
    
    JOBS REPORT DRILL-DOWN: IS DIRE DATA A BLIP OR TREND? -
CLICK HERE
    
    U.S. STOCKS RISE AFTER PAYROLLS AS AMAZON LEADS - CLICK HERE
    
    U.S. STOCK FUTURES ADD SLIGHTLY TO GAINS, YIELDS FALL, AFTER
JOBS DISAPPOINT -  CLICK HERE
    
    COULD OCTOBER PAYROLLS BE NEGATIVE? - CLICK HERE
    
    EUROPEAN EARNINGS: BETTER BUT STILL MIXED - MORGAN STANLEY -
CLICK HERE
    
    UK GILTS: TRUSSED UP? - CLICK HERE
    
    EUROPEAN SHARES BOUNCE, STILL SET FOR WEEKLY FALL - CLICK
HERE
    
    EUROPE BEFORE THE BELL: FUTURES STEADY BEFORE JOBS DATA -
CLICK HERE
    
    A NOVEMBER TO REMEMBER... - CLICK HERE
     
       

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Early trade Nov 1    https://tmsnrt.rs/4f6WHRV
Nonfarm payrolls    https://reut.rs/3AaNOYA
Inflation gauges    https://reut.rs/40sVSP5
Labor market participation    https://reut.rs/4easqAj
Unemployment by duration    https://reut.rs/3YKrmPl
Unemployment by race and ethnicity    https://reut.rs/48u6jDK
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>